Biocon

Biocon Chairperson Kiran Mazumdar-Shaw on Friday said the convergence of biological intelligence and artificial intelligence (AI) can drive a paradigm shift in medicine, enabling breakthroughs in predictive healthcare, regenerative science and lifespan management. "Biology on its own was limited in generating deeper insights, but AI tools are opening immeasurable opportunities to understand living systems," Mazumdar-Shaw said while speaking at the AI Impact Summit here. She noted that biological systems function like distributed data centres, processing information with minimal energy compared to gigawatt-powered AI systems. "Biology has a lot to teach AI in terms of how to do it with less energy, how to do it rapidly, and how to multiplex multimodal data very quickly," she said. Mazumdar-Shaw described reprogramming cells - such as converting malignant cancer cells into non-malignant ones - as the 'holy grail' of medicine. She said AI could accelerate regenerative science and hel

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase

Stocks to watch today, Friday, February 13, 2026: Market participants will keep an eye on SpiceJet, Coal India, Biocon, Infosys, Mishra Dhatu Nigam, Indraprastha Gas share prices today

Board gives in-principle nod to make Biocon Biologics a wholly owned subsidiary as Q3 net profit climbs to Rs 143.8 crore

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Stocks to watch on January 13, 2026: Stocks like TCS, HCL Technologies, Anand Rathi Wealth, Biocon and NBCC will remain in focus today

Biocon has opened a ₹4,500-crore QIP and fixed a floor price of ₹387.74 per share. The company said it may offer a discount of up to 5% and will finalise pricing with lead managers

Stocks to Watch today, January 7, 2026: Godrej Consumer, Titan, Jubilant FoodWorks, YES Bank are among key stocks that will be in focus today

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Stocks to Watch today, December 16, 2025: HCLTech, MTNL, SBI, EIH and others will remain on investors' radar today

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Brokerages say Biocon's move to fully acquire Biocon Biologics simplifies structure and unlocks value, but near-term stock pressure likely due to dilution and fundraising

Stocks to Watch today, December 8, 2025: Bajaj Finserv, ONGC, AU Small Finance Bank, P N Gadgil Jewellers, Cochin Shipyard, Delhivery, and TVS Motor Company are among the top stock to remain in focus

'Can reinvest operating cash back into biz to scale up GLP-1s'

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Biocon's board will meet on December 6 to consider acquiring Biocon Biologics shares from minority investors through cash or a share swap, and to approve fundraising options such as QIP, rights issue

MOFSL and JM Financial retained their Buy ratings, while Nuvama upgraded Biocon to Buy from Hold after the company posted a net profit of ₹85 crore in Q2FY26